From: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
Question | Response options | |
---|---|---|
1a | Is achieving a complete response or a partial response with pazopanib in first-line treatment directly correlated with better OSa? | 1 (strongly disagree) 4 (strongly agree) |
1b | Is achieving a complete or partial response with pazopanib in first-line treatment directly correlated with better PFSb? | 1 (strongly disagree) 4 (strongly agree) |
2 | Even if there is no impact on OS, is the longer PFS in first-line treatment with pazopanib sufficient for it to be considered as a standard treatment option? | 1 (strongly disagree) 4 (strongly agree) |
3 | Should OS be considered as a primary objective in first-line studies? | a) Yes b) No |
4 | When selecting pazopanib as a first-line treatment, to which parameter do you give more importance in daily clinical practice? | a) OS b) PFS c) cQoL |
5 | Does reducing the dose of pazopanib compromise its efficacy? | 1 (strongly disagree) 4 (strongly agree) |
6 | When prescribing a treatment, do you inform the patient about the different first-line treatment options in order to take into account their opinion and preference? | 1 (strongly disagree) 4 (strongly agree) |
7a | Is pazopanib an appropriate first-line treatment for patients with clear cell carcinoma, ECOGd 0, and no significant comorbidities? | 1 (strongly disagree) 4 (strongly agree) |
7b | Is pazopanib an appropriate first-line treatment for patients with brain metastases? | 1 (strongly disagree) 4 (strongly agree) |
7c | Is pazopanib an appropriate first-line treatment for patients with concomitant cardiovascular disease? | 1 (strongly disagree) 4 (strongly agree) |
7d | Is pazopanib an appropriate first-line treatment for patients with concomitant liver disease? | 1 (strongly disagree) 4 (strongly agree) |
7e | Is pazopanib an appropriate first-line treatment for patients with non-clear cell histologies? | 1 (strongly disagree) 4 (strongly agree) |
7f | Is pazopanib an appropriate first-line treatment for patients with moderate to severe renal failure (CrCle ≤ 30)? | 1 (strongly disagree) 4 (strongly agree) |
7 g | Is pazopanib an appropriate first-line treatment for patients with ECOG ≥2? | 1 (strongly disagree) 4 (strongly agree) |
7e | Is pazopanib an appropriate first-line treatment for patients with a poor prognosis? | 1 (strongly disagree) 4 (strongly agree) |
7f | Is pazopanib an appropriate first-line treatment for patients with asymptomatic heart disease and fLVEF < 50%? | 1 (strongly disagree) 4 (strongly agree) |
8 | When starting treatment with pazopanib in patients treated with oral anticoagulants, what do you do in your standard clinical practice? | a) Change treatment to gLMWH b) Continue hOAC treatment |
9a | With regard to patient age and pazopanib treatment, indicate your level of agreement with the following statement: “I do not prescribe pazopanib in patients older than 80 years of age” | 1 (strongly disagree) 4 (strongly agree) |
9b | With regard to patient age and pazopanib treatment, indicate your level of agreement with the following statement: “In patients over 70 years of age, I prescribe treatment at a dose of 800 mg/day”. | 1 (strongly disagree) 4 (strongly agree) |
10 | If biomarkers for pazopanib response were available, which would be most useful for you in your daily clinical practice? | a) Biomarkers predicting toxicity b) Biomarkers predicting efficacy |
11 | With regard to tolerability, place in order of importance, from highest to lowest, the following factors to be taken into account when prescribing pazopanib. | a) Functional status b) Concomitant diseases c) Age d) Social support |
12 | Is it advisable to temporarily suspend treatment with pazopanib, and to continue with radiological monitoring, in order to reduce pazopanib toxicity (stop-and-go strategy)? | 1 (strongly disagree) 4 (strongly agree) |
13a | If pazopanib toxicity develops, what do you do in the case of grade 2 gastrointestinal toxicity? | a) Maintain the dose b) Reduce the dose c) Discontinue treatment |
13b | If pazopanib toxicity develops, what do you do in the case of grade 3–4 gastrointestinal toxicity? | a) Maintain the dose b) Reduce the dose c) Discontinue treatment |
13c | If pazopanib toxicity develops, what do you do in the case of grade 1–2 liver toxicity (AST/ALT 2.5 times the normal value)? | a) Maintain the dose b) Reduce the dose c) Discontinue treatment |
14 | If the patient shows complete response to pazopanib, what do you do in your standard clinical practice? | a) Maintain the dose b) Adjust the therapeutic regimen c) Discontinue treatment |